Arrest functions of the MIF ligand/receptor axes in atherogenesis

Frontiers in Immunology

Volumn 4, Issue MAY, 2013, Pages

  Tillmann, Sabine ^a   Bernhagen, Jürgen ^a,b   Noels, Heidi ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Arrest; Atherosclerosis; Chemokine; Inflammation; Leukocyte recruitment; Signal transduction

Indexed keywords

ALPHA DEFENSIN; BETA DEFENSIN; CATHELICIDIN; CD74 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL3 CHEMOKINE; CYCLOPHILIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTEGRIN; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; STROMAL CELL DERIVED FACTOR 1; THIOREDOXIN; UROKINASE; Y BOX BINDING PROTEIN 1;

ATHEROGENESIS; ATHEROSCLEROSIS; CELL ADHESION; CHEMOTAXIS; HUMAN; INFLAMMATORY DISEASE; INTERNALIZATION; LEUKOCYTE; LEUKOCYTE MIGRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OLIGOMERIZATION; PERICYTE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; X RAY CRYSTALLOGRAPHY;

EID: 84883817684     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00115     Document Type: Review

References (216)

1. Al-Abed, Y., Metz, C. N., Cheng, K. F., Aljabari, B., Vanpatten, S., Blau, S., et al. (2011). Thyroxine is a potential endogenous antagonist of macrophage migration inhibitory factor (MIF) activity. Proc. Natl. Acad. Sci. U.S.A. 108, 8224-8227.
2. Allain, F., Vanpouille, C., Carpentier, M., Slomianny, M. C., Durieux, S., and Spik, G. (2002). Interaction with glycosaminoglycans is required for cyclophilin B to trigger integrin-mediated adhesion of peripheral blood T lymphocytes to extracellular matrix. Proc. Natl. Acad. Sci. U.S.A. 99, 2714-2719.
3. Amin, M. A., Haas, C. S., Zhu, K., Mansfield, P. J., Kim, M. J., Lackowski, N. P., et al. (2006). Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFkappaB. Blood 107, 2252-2261.
4. Amin, M. A., Volpert, O. V., Woods, J. M., Kumar, P., Harlow, L. A., and Koch, A. E. (2003). Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ. Res. 93, 321-329.
5. Andersson, U., Wang, H., Palmblad, K., Aveberger, A. C., Bloom, O., Erlandsson-Harris, H., et al. (2000). High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192, 565-570.
6. Atsumi, T., Nishihira, J., Makita, Z., and Koike, T. (2000). Enhancement of oxidised low-density lipoprotein uptake by macrophages in response to macrophage migration inhibitory factor. Cytokine 12, 1553-1556.
7. Bacher, M., Metz, C. N., Calandra, T., Mayer, K., Chesney, J., Lohoff, M., et al. (1996). An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl. Acad. Sci. U.S.A. 93, 7849-7854.
8. Bajetto, A., Bonavia, R., Barbero, S., and Schettini, G. (2002). Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J. Neurochem. 82, 1311-1329.
9. Balabanian, K., Lagane, B., Infantino, S., Chow, K. Y., Harriague, J., Moepps, B., et al. (2005). The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. Biol. Chem. 280, 35760-35766.
10. Bernhagen, J., Calandra, T., Mitchell, R. A., Martin, S. B., Tracey, K. J., Voelter, W., et al. (1993). MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365, 756-759.
11. Bernhagen, J., Krohn, R., Lue, H., Gregory, J. L., Zernecke, A., Koenen, R. R., et al. (2007). MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13, 587-596.
12. Bernhagen, J., Mitchell, R. A., Calandra, T., Voelter, W., Cerami, A., and Bucala, R. (1994). Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33, 14144-14155.
13. Bertini, R., Howard, O. M., Dong, H. F., Oppenheim, J. J., Bizzarri, C., Sergi, R., et al. (1999). Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J. Exp. Med. 189, 1783-1789.
14. Binsky, I., Haran, M., Starlets, D., Gore, Y., Lantner, F., Harpaz, N., et al. (2007). IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc. Natl. Acad. Sci. U.S.A. 104, 13408-13413.
15. Biragyn, A., Ruffini, P. A., Leifer, C. A., Klyushnenkova, E., Shakhov, A., Chertov, O., et al. (2002). Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298, 1025-1029.
16. Bloom, B. R., and Bennett, B. (1966). Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153, 80-82.
17. Boisvert, W. A., Rose, D. M., Johnson, K. A., Fuentes, M. E., Lira, S. A., Curtiss, L. K., et al. (2006). Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am. J. Pathol. 168, 1385-1395.
18. Boisvert, W. A., Santiago, R., Curtiss, L. K., and Terkeltaub, R. A. (1998). A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J. Clin. Invest. 101, 353-363.
19. Boldajipour, B., Mahabaleshwar, H., Kardash, E., Reichman-Fried, M., Blaser, H., Minina, S., et al. (2008). Control of chemokine-guided cell migration by ligand sequestration. Cell 132, 463-473.
20. Borghese, F., and Clanchy, F. I. (2011). CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opin. Ther. Targets 15, 237-251.
21. Brandau, S., Jakob, M., Hemeda, H., Bruderek, K., Janeschik, S., Bootz, F., et al. (2010). Tissue-resident mesenchymal stem cells attract peripheral blood neutrophils and enhance their inflammatory activity in response to microbial challenge. J. Leukoc. Biol. 88, 1005-1015.
22. Bruhl, H., Cohen, C. D., Linder, S., Kretzler, M., Schlondorff, D., and Mack, M. (2003). Post-translational and cell type-specific regulation of CXCR4 expression by cytokines. Eur. J. Immunol. 33, 3028-3037.
23. Burger-Kentischer, A., Gobel, H., Kleemann, R., Zernecke, A., Bucala, R., Leng, L., et al. (2006). Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis 184, 28-38.
24. Burger-Kentischer, A., Goebel, H., Seiler, R., Fraedrich, G., Schaefer, H. E., Dimmeler, S., et al. (2002). Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 105, 1561-1566.
25. Burns, J. M., Summers, B. C., Wang, Y., Melikian, A., Berahovich, R., Miao, Z., et al. (2006). A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 203, 2201-2213.
26. Calandra, T., Bernhagen, J., Metz, C. N., Spiegel, L. A., Bacher, M., Donnelly, T., et al. (1995). MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377, 68-71.
27. Calandra, T., Bernhagen, J., Mitchell, R. A., and Bucala, R. (1994). The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179, 1895-1902.
28. Calandra, T., and Roger, T. (2003). Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol. 3, 791-800.
29. Calandra, T., Spiegel, L. A., Metz, C. N., and Bucala, R. (1998). Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc. Natl. Acad. Sci. U.S.A. 95, 11383-11388.
30. Charo, I. F., and Ransohoff, R. M. (2006). The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621.
31. Chen, L., Yang, G., Zhang, X., Wu, J., Gu, Q., Wei, M., et al. (2009). Induction of MIF expression by oxidized LDL via activation of NF-?B in vascular smooth muscle cells. Atherosclerosis 207, 428-433.
32. Chen, Z., Sakuma, M., Zago, A. C., Zhang, X., Shi, C., Leng, L., et al. (2004). Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler. Thromb. Vasc. Biol. 24, 709-714.
33. Cheng, Q., McKeown, S. J., Santos, L., Santiago, F. S., Khachigian, L. M., Morand, E. F., et al. (2010). Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules. J. Immunol. 185, 1238-1247.
34. Chesney, J., Metz, C., Bacher, M., Peng, T., Meinhardt, A., and Bucala, R. (1999). An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med. 5, 181-191.
35. Cho, Y., Crichlow, G. V., Vermeire, J. J., Leng, L., Du, X., Hodsdon, M. E., et al. (2010). Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc. Natl. Acad. Sci. U.S.A. 107, 11313-11318.
36. Cho, Y., Jones, B. F., Vermeire, J. J., Leng, L., Difedele, L., Harrison, L. M., et al. (2007). Structural and functional characterization of a secreted hookworm Macrophage Migration Inhibitory Factor (MIF) that interacts with the human MIF receptor CD74. J. Biol. Chem. 282, 23447-23456.
37. Chuntharapai, A., Lee, J., Hebert, C. A., and Kim, K. J. (1994). Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J. Immunol. 153, 5682-5688.
38. Clark-Lewis, I., Kim, K. S., Rajarathnam, K., Gong, J. H., Dewald, B., Moser, B., et al. (1995). Structure-activity relationships of chemokines. J. Leukoc. Biol. 57, 703-711.
39. Clore, G. M., Appella, E., Yamada, M., Matsushima, K., and Gronenborn, A. M. (1990). Three-dimensional structure of interleukin 8 in solution. Biochemistry 29, 1689-1696.
40. Col-Araz, N., Oguzkan-Balci, S., Baspinar, O., Sever, T., Balat, A., and Pehlivan, S. (2012). Mannose binding lectin and macrophage migration inhibitory factor gene polymorphisms in Turkish children with cardiomyopathy: no association with MBL2 codon 54 A/B genotype, but an association between MIF -173 CC genotype. Int. J. Med. Sci. 9, 506-512.
41. Colley, N. J., Baker, E. K., Stamnes, M. A., and Zuker, C. S. (1991). The cyclophilin homolog ninaA is required in the secretory pathway. Cell 67, 255-263.
42. Contento, R. L., Molon, B., Boularan, C., Pozzan, T., Manes, S., Marullo, S., et al. (2008). CXCR4-CCR5: a couple modulating T cell functions. Proc. Natl. Acad. Sci. U.S.A. 105, 10101-10106.
43. Dambly-Chaudiere, C., Cubedo, N., and Ghysen, A. (2007). Control of cell migration in the development of the posterior lateral line: antagonistic interactions between the chemokine receptors CXCR4 and CXCR7/RDC1. BMC Dev. Biol. 7:23. doi:10.1186/1471-213X-7-23
44. David, J. R. (1966). Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. U.S.A. 56, 72-77.
45. Degryse, B., and de Virgilio, M. (2003). The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett. 553, 11-17.
46. Dessein, A. F., Stechly, L., Jonckheere, N., Dumont, P., Monte, D., Leteurtre, E., et al. (2010). Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res. 70, 4644-4654.
47. Donn, R. P., Shelley, E., Ollier, W. E., and Thomson, W. (2001). A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 44, 1782-1785.
48. El-Turk, F., Cascella, M., Ouertatani-Sakouhi, H., Narayanan, R. L., Leng, L., Bucala, R., et al. (2008). The conformational flexibility of the carboxy terminal residues 105-114 is a key modulator of the catalytic activity and stability of macrophage migration inhibitory factor. Biochemistry 47, 10740-10756.
49. El-Turk, F., Fauvet, B., Ashrafi, A., Ouertatani-Sakouhi, H., Cho, M. K., Neri, M., et al. (2012). Characterization of molecular determinants of the conformational stability of macrophage migration inhibitory factor: leucine 46 hydrophobic pocket. PLoS ONE 7:e45024. doi:10.1371/journal.pone.0045024
50. Fan, H, Hall, P., Santos, L. L., Gregory, J. L., Fingerle-Rowson, G., Bucala, R., et al. (2011). Macrophage migration inhibitory factor and CD74 regulate macrophage chemotactic responses via MAPK and Rho GTPase. J. Immunol. 186, 4915-4924.
51. Fernandez, E. J., and Lolis, E. (2002). Structure, function, and inhibition of chemokines. Annu. Rev. Pharmacol. Toxicol. 42, 469-499.
52. Fingerle-Rowson, G., Kaleswarapu, D. R., Schlander, C., Kabgani, N., Brocks, T., Reinart, N., et al. (2009). A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol. Cell. Biol. 29, 1922-1932.
53. Fiuza, C., Bustin, M., Talwar, S., Tropea, M., Gerstenberger, E., Shelhamer, J. H., et al. (2003). Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101, 2652-2660.
54. Flieger, O., Engling, A., Bucala, R., Lue, H., Nickel, W., and Bernhagen, J. (2003). Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett. 551, 78-86.
55. Frye, B. C., Halfter, S., Djudjaj, S., Muehlenberg, P., Weber, S., Raffetseder, U., et al. (2009). Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO Rep. 10, 783-789.
56. Gao, H., Neff, T. A., Guo, R. F., Speyer, C. L., Sarma, J. V., Tomlins, S., et al. (2005). Evidence for a functional role of the second C5a receptor C5L2. FASEB J. 19, 1003-1005.
57. Garai, J., and Lorand, T. (2009). Macrophage migration inhibitory factor (MIF) tautomerase inhibitors as potential novel anti-inflammatory agents: current developments. Curr. Med. Chem. 16, 1091-1114.
58. Gordin, M., Tesio, M., Cohen, S., Gore, Y., Lantner, F., Leng, L., et al. (2010). c-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74. J. Immunol. 185, 2020-2031.
59. Gore, Y., Starlets, D., Maharshak, N., Becker-Herman, S., Kaneyuki, U., Leng, L., et al. (2008). Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J. Biol. Chem. 283, 2784-2792.
60. Govindaraju, V., Michoud, M. C., Al-Chalabi, M., Ferraro, P., Powell, W. S., and Martin, J. G. (2006). Interleukin-8: novel roles in human airway smooth muscle cell contraction and migration. Am. J. Physiol. Cell Physiol. 291, C957-965.
61. Gregory, J. L., Hall, P., Leech, M., Morand, E. F., and Hickey, M. J. (2009). Independent roles of macrophage migration inhibitory factor and endogenous, but not exogenous glucocorticoids in regulating leukocyte trafficking. Microcirculation 16, 735-748.
62. Gregory, J. L., Leech, M. T., David, J. R., Yang, Y. H., Dacumos, A., and Hickey, M. J. (2004). Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. Arthritis Rheum. 50, 3023-3034.
63. Gregory, J. L., Morand, E. F., McKeown, S. J., Ralph, J. A., Hall, P., Yang, Y. H., et al. (2006). Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J. Immunol. 177, 8072-8079.
64. Gupta, S. K., Lysko, P. G., Pillarisetti, K., Ohlstein, E., and Stadel, J. M. (1998). Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J. Biol. Chem. 273, 4282-4287.
65. Hamatake, M., Aoki, T., Futahashi, Y., Urano, E., Yamamoto, N., and Komano, J. (2009). Ligand-independent higher-order multimerization of CXCR4, a G-protein-coupled chemokine receptor involved in targeted metastasis. Cancer Sci. 100, 95-102.
66. Hattermann, K., Held-Feindt, J., Lucius, R., Muerkoster, S. S., Penfold, M. E., Schall, T. J., et al. (2010). The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res. 70, 3299-3308.
67. Hebert, C. A., Vitangcol, R. V., and Baker, J. B. (1991). Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J. Biol. Chem. 266, 18989-18994.
68. Heinrichs, D., Knauel, M., Offermanns, C., Berres, M. L., Nellen, A., Leng, L., et al. (2011). Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc. Natl. Acad. Sci. U.S.A. 108, 17444-17449.
69. Herder, C., Illig, T., Baumert, J., Muller, M., Klopp, N., Khuseyinova, N., et al. (2008). Macrophage migration inhibitory factor (MIF) and risk for coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Atherosclerosis 200, 380-388.
70. Hermanowski-Vosatka, A., Mundt, S. S., Ayala, J. M., Goyal, S., Hanlon, W. A., Czerwinski, R. M., et al. (1999). Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Biochemistry 38, 12841-12849.
71. Hoover, D. M., Boulegue, C., Yang, D., Oppenheim, J. J., Tucker, K., Lu, W., et al. (2002). The structure of human macrophage inflammatory protein-3alpha/CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins. J. Biol. Chem. 277, 37647-37654.
72. Infantino, S., Moepps, B., and Thelen, M. (2006). Expression and regulation of the orphan receptor RDC1 and its putative ligand in human dendritic and B cells. J. Immunol. 176, 2197-2207.
73. Ingersoll, M. A., Spanbroek, R., Lottaz, C., Gautier, E. L., Frankenberger, M., Hoffmann, R., et al. (2010). Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 115, e10-e19.
74. Jung, H., Seong, H. A., and Ha, H. (2008). Critical role of cysteine residue 81 of macrophage migration inhibitory factor (MIF) in MIF-induced inhibition of p53 activity. J. Biol. Chem. 283, 20383-20396.
75. Kerschbaumer, R. J., Rieger, M., Volkel, D., Le Roy, D., Roger, T., Garbaraviciene, J., et al. (2012). Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the beta-sheet structure of MIF. J. Biol. Chem. 287, 7446-7455.
76. Khromykh, L. M., Kulikova, N. L., Anfalova, T. V., Muranova, T. A., Abramov, V. M., Vasiliev, A. M., et al. (2007). Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells. Cell. Immunol. 249, 46-53.
77. Kim, S., Miska, K. B., Jenkins, M. C., Fetterer, R. H., Cox, C. M., Stuard, L. H., et al. (2010). Molecular cloning and functional characterization of the avian macrophage migration inhibitory factor (MIF). Dev. Comp. Immunol. 34, 1021-1032.
78. Kitani, A., Nakashima, N., Izumihara, T., Inagaki, M., Baoui, X., Yu, S., et al. (1998). Soluble VCAM-1 induces chemotaxis of Jurkat and synovial fluid T cells bearing high affinity very late antigen-4. J. Immunol. 161, 4931-4938.
79. Kleemann, R., Hausser, A., Geiger, G., Mischke, R., Burger-Kentischer, A., Flieger, O., et al. (2000). Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408, 211-216.
80. Kleemann, R., Kapurniotu, A., Frank, R. W., Gessner, A., Mischke, R., Flieger, O., et al. (1998). Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J. Mol. Biol. 280, 85-102.
81. Kleemann, R., Kapurniotu, A., Mischke, R., Held, J., and Bernhagen, J. (1999). Characterization of catalytic centre mutants of macrophage migration inhibitory factor (MIF) and comparison to Cys81Ser MIF. Eur. J. Biochem. 261, 753-766.
82. Koenen, R. R., and Weber, C. (2010). Therapeutic targeting of chemokine interactions in atherosclerosis. Nat. Rev. Drug Discov. 9, 141-153.
83. Kong, Y. Z., Huang, X. R., Ouyang, X., Tan, J. J., Fingerle-Rowson, G., Bacher, M., et al. (2005a). Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques. Cardiovasc. Res. 65, 272-282.
84. Kong, Y. Z., Yu, X., Tang, J. J., Ouyang, X., Huang, X. R., Fingerle-Rowson, G., et al. (2005b). Macrophage migration inhibitory factor induces MMP-9 expression: implications for destabilization of human atherosclerotic plaques. Atherosclerosis 178, 207-215.
85. Kraemer, S., Lue, H., Zernecke, A., Kapurniotu, A., Andreetto, E., Frank, R., et al. (2011). MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism. FASEB J. 25, 894-906.
86. Kraemer, S., Rajabi, S. A., El Bounkari, O., and Bernhagen, J. (2013). Hetero-oligomerization of chemokine receptors: diversity and relevance for function. Curr. Med. Chem. [Epub ahead of print].
87. Kraemer, S., Weber, C., and Bernhagen, J. (2012). "MIF and the chemokine axis," in The MIF Handbook, Chap. I-2, ed. R. Bucala (Singapore: World Scientific Publishing), 23-53.
88. Kumar, R., Tripathi, V., Ahmad, M., Nath, N., Mir, R. A., Chauhan, S. S., et al. (2012). CXCR7 mediated Gialpha independent activation of ERK and Akt promotes cell survival and chemotaxis in T cells. Cell. Immunol. 272, 230-241.
89. Lan, H. Y., Bacher, M., Yang, N., Mu, W., Nikolic-Paterson, D. J., Metz, C., et al. (1997). The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J. Exp. Med. 185, 1455-1465.
90. Lee, C. Y., Su, M. J., Huang, C. Y., Chen, M. Y., Hsu, H. C., Lin, C. Y., et al. (2012). Macrophage migration inhibitory factor increases cell motility and up-regulates alphavbeta3 integrin in human chondrosarcoma cells. J. Cell. Biochem. 113, 1590-1598.
91. Lefort, C. T., and Ley, K. (2012). Neutrophil arrest by LFA-1 activation. Front. Immunol. 3:157. doi:10.3389/fimmu.2012.00157
92. Leng, L., Metz, C. N., Fang, Y., Xu, J., Donnelly, S., Baugh, J., et al. (2003). MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197, 1467-1476.
93. Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F., and Lagane, B. (2009). CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113, 6085-6093.
94. Ley, K., Laudanna, C., Cybulsky, M. I., and Nourshargh, S. (2007). Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678-689.
95. Liang, X. (2008). CXCR4, inhibitors and mechanisms of action. Chem. Biol. Drug Des. 72, 97-110.
96. Lin, S. G., Yu, X. Y., Chen, Y. X., Huang, X. R., Metz, C., Bucala, R., et al. (2000). De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ. Res. 87, 1202-1208.
97. Liu, L., Chen, J., Ji, C., Zhang, J., Sun, J., Li, Y., et al. (2008). Macrophage migration inhibitory factor (MIF) interacts with Bim and inhibits Bim-mediated apoptosis. Mol. Cells 26, 193-199.
98. Lue, H., Dewor, M., Leng, L., Bucala, R., and Bernhagen, J. (2011). Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell. Signal. 23, 135-144.
99. Lue, H., Kapurniotu, A., Fingerle-Rowson, G., Roger, T., Leng, L., Thiele, M., et al. (2006). Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell. Signal. 18, 688-703.
100. Lue, H., Thiele, M., Franz, J., Dahl, E., Speckgens, S., Leng, L., et al. (2007). Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26, 5046-5059.
101. Luedike, P., Hendgen-Cotta, U. B., Sobierajski, J., Totzeck, M., Reeh, M., Dewor, M., et al. (2012). Cardioprotection through S-nitros(yl)ation of macrophage migration inhibitory factor. Circulation 125, 1880-1889.
102. Luker, K. E., Gupta, M., and Luker, G. D. (2009). Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J. 23, 823-834.
103. Ma, Q., Jones, D., Borghesani, P. R., Segal, R. A., Nagasawa, T., Kishimoto, T., et al. (1998). Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 95, 9448-9453.
104. Makino, A., Nakamura, T., Hirano, M., Kitta, Y., Sano, K., Kobayashi, T., et al. (2010). High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis 213, 573-578.
105. Martin-Ventura, J. L., Madrigal-Matute, J., Munoz-Garcia, B., Blanco-Colio, L. M., Van Oostrom, M., Zalba, G., et al. (2009). Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. Cardiovasc. Res. 83, 586-594.
106. Merk, M., Mitchell, R. A., Endres, S., and Bucala, R. (2012). D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. Cytokine 59, 10-17.
107. Miller, E. J., Li, J., Leng, L., McDonald, C., Atsumi, T., Bucala, R., et al. (2008). Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 451, 578-582.
108. Milligan, G. (2007). G protein-coupled receptor dimerisation: molecular basis and relevance to function. Biochim. Biophys. Acta 1768, 825-835.
109. Mischke, R., Kleemann, R., Brunner, H., and Bernhagen, J. (1998). Cross-linking and mutational analysis of the oligomerization state of the cytokine macrophage migration inhibitory factor (MIF). FEBS Lett. 427, 85-90.
110. Mitchell, R. A., Liao, H., Chesney, J., Fingerle-Rowson, G., Baugh, J., David, J., et al. (2002). Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. U.S.A. 99, 345-350.
111. Mitchell, R. A., Metz, C. N., Peng, T., and Bucala, R. (1999). Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J. Biol. Chem. 274, 18100-18106.
112. Mohle, R., Bautz, F., Rafii, S., Moore, M. A., Brugger, W., and Kanz, L. (1998). The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 91, 4523-4530.
113. Montresor, A., Toffali, L., Constantin, G., and Laudanna, C. (2012). Chemokines and the signaling modules regulating integrin affinity. Front. Immunol. 3:127. doi:10.3389/fimmu.2012.00127
114. Morand, E. F., Leech, M., and Bernhagen, J. (2006). MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat. Rev. Drug Discov. 5, 399-410.
115. Muller, I. I., Muller, K. A., Schonleber, H., Karathanos, A., Schneider, M., Jorbenadze, R., et al. (2012). Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response. PLoS ONE 7:e38376. doi:10.1371/journal.pone.0038376
116. Murdoch, C., Monk, P. N., and Finn, A. (1999). Cxc chemokine receptor expression on human endothelial cells. Cytokine 11, 704-712.
117. Murfee, W. L., Skalak, T. C., and Peirce, S. M. (2005). Differential arterial/venous expression of NG2 proteoglycan in perivascular cells along microvessels: identifying a venule-specific phenotype. Microcirculation 12, 151-160.
118. Murphy, P. M., Baggiolini, M., Charo, I. F., Hebert, C. A., Horuk, R., Matsushima, K., et al. (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52, 145-176.
119. Neel, N. F., Barzik, M., Raman, D., Sobolik-Delmaire, T., Sai, J., Ham, A. J., et al. (2009). VASP is a CXCR2-interacting protein that regulates CXCR2-mediated polarization and chemotaxis. J. Cell Sci. 122, 1882-1894.
120. Neel, N. F., Sai, J., Ham, A. J., Sobolik-Delmaire, T., Mernaugh, R. L., and Richmond, A. (2011). IQGAP1 is a novel CXCR2-interacting protein and essential component of the "chemosynapse." PLoS ONE 6:e23813. doi:10.1371/journal.pone.0023813
121. Nguyen, M. T., Beck, J., Lue, H., Funfzig, H., Kleemann, R., Koolwijk, P., et al. (2003). A 16-residue peptide fragment of macrophage migration inhibitory factor. J. Biol. Chem. 278, 33654-33671.
122. Nie, Y., Waite, J., Brewer, F., Sunshine, M. J., Littman, D. R., and Zou, Y. R. (2004). The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J. Exp. Med. 200, 1145-1156.
123. Nishihira, J., Koyama, Y., and Mizue, Y. (1998). Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine 10, 199-205.
124. Noels, H., Bernhagen, J., and Weber, C. (2009). Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. Trends Cardiovasc. Med. 19, 76-86.
125. Noels, H., Bernhagen, J., and Weber, C. (2012). "MIF in atherosclerosis," in MIF: Most Interesting Factor Revisited, Chap. V-1, ed. R. Bucala (Singapore: World Scientific Publishing), 321-358.
126. Ogawa, H., Nishihira, J., Sato, Y., Kondo, M., Takahashi, N., Oshima, T., et al. (2000). An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine 12, 309-314.
127. Oppenheim, J. J., Biragyn, A., Kwak, L. W., and Yang, D. (2003). Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann. Rheum. Dis. 62(Suppl. 2), ii17-21.
128. Oppenheim, J. J., and Yang, D. (2005). Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17, 359-365.
129. Orita, M., Yamamoto, S., Katayama, N., Aoki, M., Takayama, K., Yamagiwa, Y., et al. (2001). Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography. J. Med. Chem. 44, 540-547.
130. Ouertatani-Sakouhi, H., El-Turk, F., Fauvet, B., Cho, M. K., Pinar Karpinar, D., Le Roy, D., et al. (2010). Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action. J. Biol. Chem. 285, 26581-26598.
131. Palomino-Morales, R., Gonzalez-Juanatey, C., Vazquez-Rodriguez, T. R., Torres, O., Miranda-Filloy, J. A., Llorca, J., et al. (2010). Lack of association between macrophage migration inhibitory factor-173 gene polymorphism with disease susceptibility and cardiovascular risk in rheumatoid arthritis patients from northwestern Spain. Clin. Exp. Rheumatol. 28, 68-72.
132. Pan, J. H., Sukhova, G. K., Yang, J. T., Wang, B., Xie, T., Fu, H., et al. (2004). Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 109, 3149-3153.
133. Parenty, G., Appelbe, S., and Milligan, G. (2008). CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Biochem. J. 412, 245-256.
134. Philo, J. S., Yang, T. H., and Labarre, M. (2004). Re-examining the oligomerization state of macrophage migration inhibitory factor (MIF) in solution. Biophys. Chem. 108, 77-87.
135. Price, E. R., Jin, M., Lim, D., Pati, S., Walsh, C. T., and McKeon, F. D. (1994). Cyclophilin B trafficking through the secretory pathway is altered by binding of cyclosporin A. Proc. Natl. Acad. Sci. U.S.A. 91, 3931-3935.
136. Pullerits, R., Jonsson, I. M., Verdrengh, M., Bokarewa, M., Andersson, U., Erlandsson-Harris, H., et al. (2003). High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum. 48, 1693-1700.
137. Qi, D., Hu, X., Wu, X., Merk, M., Leng, L., Bucala, R., et al. (2009). Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. J. Clin. Invest. 119, 3807-3816.
138. Quax, P. H. A., Boxman, I. L. A., van Kesteren, J. H., Verheijen, J. H., and Ponec, M. (1994). Plasminogen activators are involved in keratinocyte and fibroblast migration in wounded cultures in vitro. Fibrinolysis 8, 221-228.
139. Rajagopal, S., Kim, J., Ahn, S., Craig, S., Lam, C. M., Gerard, N. P., et al. (2010). Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc. Natl. Acad. Sci. U.S.A. 107, 628-632.
140. Rajagopalan, L., and Rajarathnam, K. (2006). Structural basis of chemokine receptor function - a model for binding affinity and ligand selectivity. Biosci. Rep. 26, 325-339.
141. Rauen, T., Raffetseder, U., Frye, B. C., Djudjaj, S., Muhlenberg, P. J., Eitner, F., et al. (2009). YB-1 acts as a ligand for Notch-3 receptors and modulates receptor activation. J. Biol. Chem. 284, 26928-26940.
142. Reidy, T., Rittenberg, A., Dwyer, M., D'Ortona, S., Pier, G., and Gadjeva, M. (2013). Homotrimeric MIF drives inflammatory responses in the corneal epithelium by promoting caveolin-rich platform assembly in response to infection. J. Biol. Chem. 288, 8269-8278.
143. Reinart, N., Nguyen, P. H., Boucas, J., Rosen, N., Kvasnicka, H. M., Heukamp, L., et al. (2013). Delayed developent of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. Blood 121, 812-821.
144. Ren, Y., Tsui, H. T., Poon, R. T., Ng, I. O., Li, Z., Chen, Y., et al. (2003). Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int. J. Cancer 107, 22-29.
145. Resnati, M., Pallavicini, I., Wang, J. M., Oppenheim, J., Serhan, C. N., Romano, M., et al. (2002). The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. U.S.A. 99, 1359-1364.
146. Riedemann, E., Rojas, C., and Quevedo, I. (2004). Somatotropic pituitary tumor in a patient with a previous ovarian strumal carcinoid. Report of one case. Rev. Med. Chil. 132, 857-859.
147. Roovers, K., and Assoian, R. K. (2003). Effects of rho kinase and actin stress fibers on sustained extracellular signal-regulated kinase activity and activation of G(1) phase cyclin-dependent kinases. Mol. Cell. Biol. 23, 4283-4294.
148. Rosengren, E., Aman, P., Thelin, S., Hansson, C., Ahlfors, S., Bjork, P., et al. (1997). The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett. 417, 85-88.
149. Roychoudhury, P. K., Khaparde, S. S., Mattiasson, B., and Kumar, A. (2006). Synthesis, regulation and production of urokinase using mammalian cell culture: a comprehensive review. Biotechnol. Adv. 24, 514-528.
150. Saini, V., Marchese, A., and Majetschak, M. (2010). CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. J. Biol. Chem. 285, 15566-15576.
151. Sainz, J., and Sata, M. (2007). CXCR4, a key modulator of vascular progenitor cells. Arterioscler. Thromb. Vasc. Biol. 27, 263-265.
152. Santos, L. L., Fan, H., Hall, P., Ngo, D., Mackay, C. R., Fingerle-Rowson, G., et al. (2011). Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice. Arthritis Rheum. 63, 960-970.
153. Schecter, A. D., Berman, A. B., Yi, L., Mosoian, A., McManus, C. M., Berman, J. W., et al. (2001). HIV envelope gp120 activates human arterial smooth muscle cells. Proc. Natl. Acad. Sci. U.S.A. 98, 10142-10147.
154. Schiraldi, M., Raucci, A., Munoz, L. M., Livoti, E., Celona, B., Venereau, E., et al. (2012). HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 209, 551-563.
155. Schmeisser, A., Marquetant, R., Illmer, T., Graffy, C., Garlichs, C. D., Bockler, D., et al. (2005). The expression of macrophage migration inhibitory factor 1alpha (MIF 1alpha) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instability. Atherosclerosis 178, 83-94.
156. Schober, A., Bernhagen, J., Thiele, M., Zeiffer, U., Knarren, S., Roller, M., et al. (2004). Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 109, 380-385.
157. Schrans-Stassen, B. H., Lue, H., Sonnemans, D. G., Bernhagen, J., and Post, M. J. (2005). Stimulation of vascular smooth muscle cell migration by macrophage migration inhibitory factor. Antioxid. Redox Signal. 7, 1211-1216.
158. Schwartz, V., Lue, H., Kraemer, S., Korbiel, J., Krohn, R., Ohl, K., et al. (2009). A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett. 583, 2749-2757.
159. Schwertassek, U., Balmer, Y., Gutscher, M., Weingarten, L., Preuss, M., Engelhard, J., et al. (2007). Selective redox regulation of cytokine receptor signaling by extracellular thioredoxin-1. EMBO J. 26, 3086-3097.
160. Shi, X., Leng, L., Wang, T., Wang, W., Du, X., Li, J., et al. (2006). CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25, 595-606.
161. Shimizu, S., Brown, M., Sengupta, R., Penfold, M. E., and Meucci, O. (2011). CXCR7 protein expression in human adult brain and differentiated neurons. PLoS ONE 6:e20680. doi:10.1371/journal.pone.0020680
162. Shimizu, T., Nishihira, J., Watanabe, H., Abe, R., Honda, A., Ishibashi, T., et al. (2004). Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells. J. Biol. Chem. 279, 13729-13737.
163. Simons, D., Grieb, G., Hristov, M., Pallua, N., Weber, C., Bernhagen, J., et al. (2011). Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. J. Cell. Mol. Med. 15, 668-678.
164. Smith, D. F., Deem, T. L., Bruce, A. C., Reutershan, J., Wu, D., and Ley, K. (2006). Leukocyte phosphoinositide-3 kinase {gamma} is required for chemokine-induced, sustained adhesion under flow in vivo. J. Leukoc. Biol. 80, 1491-1499.
165. Soehnlein, O., Wantha, S., Simsekyilmaz, S., Doring, Y., Megens, R. T., Mause, S. F., et al. (2011). Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci. Transl. Med. 3, 103ra198.
166. Sozzani, S., Sallusto, F., Luini, W., Zhou, D., Piemonti, L., Allavena, P., et al. (1995). Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J. Immunol. 155, 3292-3295.
167. Stadtmann, A., and Zarbock, A. (2012). CXCR2: from bench to bedside. Front. Immunol. 3:263. doi:10.3389/fimmu.2012.00263
168. Stark, K., Eckart, A., Haidari, S., Tirniceriu, A., Lorenz, M., Von Bruhl, M. L., et al. (2013). Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and "instruct" them with pattern-recognition and motility programs. Nat. Immunol. 14, 41-51.
169. Stein, R., Mattes, M. J., Cardillo, T. M., Hansen, H. J., Chang, C. H., Burton, J., et al. (2007). CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin. Cancer Res. 13, 5556s-5563s.
170. Sugimoto, H., Suzuki, M., Nakagawa, A., Tanaka, I., and Nishihira, J. (1996). Crystal structure of macrophage migration inhibitory factor from human lymphocyte at 2.1 A resolution. FEBS Lett. 389, 145-148.
171. Sugimoto, H., Taniguchi, M., Nakagawa, A., Tanaka, I., Suzuki, M., and Nishihira, J. (1999). Crystal structure of human D-dopachrome tautomerase, a homologue of macrophage migration inhibitory factor, at 1.54 A resolution. Biochemistry 38, 3268-3279.
172. Sun, H. W., Bernhagen, J., Bucala, R., and Lolis, E. (1996a). Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. U.S.A. 93, 5191-5196.
173. Sun, H. W., Swope, M., Cinquina, C., Bedarkar, S., Bernhagen, J., Bucala, R., et al. (1996b). The subunit structure of human macrophage migration inhibitory factor: evidence for a trimer. Protein Eng. 9, 631-635.
174. Sun, J., Hartvigsen, K., Chou, M. Y., Zhang, Y., Sukhova, G. K., Zhang, J., et al. (2010). Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation 122, 808-820.
175. Sunderkotter, C., Nikolic, T., Dillon, M. J., Van Rooijen, N., Stehling, M., Drevets, D. A., et al. (2004). Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J. Immunol. 172, 4410-4417.
176. Suzuki, J., Jin, Z. G., Meoli, D. F., Matoba, T., and Berk, B. C. (2006). Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ. Res. 98, 811-817.
177. Swant, J. D., Rendon, B. E., Symons, M., and Mitchell, R. A. (2005). Rho GTPase-dependent signaling is required for macrophage migration inhibitory factor-mediated expression of cyclin D1. J. Biol. Chem. 280, 23066-23072.
178. Takahashi, K., Koga, K., Linge, H. M., Zhang, Y., Lin, X., Metz, C. N., et al. (2009). Macrophage CD74 contributes to MIF-induced pulmonary inflammation. Respir. Res. 10, 33.
179. Takahashi, K., Uwabe, Y., Sawasaki, Y., Kiguchi, T., Nakamura, H., Kashiwabara, K., et al. (1998). Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells. Am. J. Physiol. 275, L47-54.
180. Tarnowski, M., Grymula, K., Liu, R., Tarnowska, J., Drukala, J., Ratajczak, J., et al. (2010). Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts. Mol. Cancer Res. 8, 1328-1343.
181. Tereshchenko, I. P., Petrkova, J., Mrazek, F., Lukl, J., Maksimov, V. N., Romaschenko, A. G., et al. (2009). The macrophage migration inhibitory factor (MIF) gene polymorphism in Czech and Russian patients with myocardial infarction. Clin. Chim. Acta 402, 199-202.
182. Thelen, M. (2001). Dancing to the tune of chemokines. Nat. Immunol. 2, 129-134.
183. Thelen, M., and Didichenko, S. A. (1997). G-protein coupled receptor-mediated activation of PI 3-kinase in neutrophils. Ann. N. Y. Acad. Sci. 832, 368-382.
184. Thelen, M., Munoz, L. M., Rodriguez-Frade, J. M., and Mellado, M. (2010). Chemokine receptor oligomerization: functional considerations. Curr. Opin. Pharmacol. 10, 38-43.
185. Thelen, M., and Thelen, S. (2008). CXCR7, CXCR4 and CXCL12: an eccentric trio? J. Neuroimmunol. 198, 9-13.
186. Tokuhira, M., Hosaka, S., Volin, M. V., Haines, G. K. III, Katschke, K. J. Jr., Kim, S., et al. (2000). Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum. 43, 1122-1133.
187. Trettel, F., Di Bartolomeo, S., Lauro, C., Catalano, M., Ciotti, M. T., and Limatola, C. (2003). Ligand-independent CXCR2 dimerization. J. Biol. Chem. 278, 40980-40988.
188. van Zoelen, M. A., Yang, H., Florquin, S., Meijers, J. C., Akira, S., Arnold, B., et al. (2009). Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 31, 280-284.
189. Vera, P. L., Iczkowski, K. A., Wang, X., and Meyer-Siegler, K. L. (2008). Cyclophosphamide-induced cystitis increases bladder CXCR4 expression and CXCR4-macrophage migration inhibitory factor association. PLoS ONE 3:e3898. doi:10.1371/journal.pone.0003898
190. Verschuren, L., Kooistra, T., Bernhagen, J., Voshol, P. J., Ouwens, D. M., van Erk, M., et al. (2009). MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ. Res. 105, 99-107.
191. Verschuren, L., Lindeman, J. H., van Bockel, J. H., Abdul-Hussien, H., Kooistra, T., and Kleemann, R. (2005). Up-regulation and coexpression of MIF and matrix metalloproteinases in human abdominal aortic aneurysms. Antioxid. Redox Signal. 7, 1195-1202.
192. Wakasugi, K., and Schimmel, P. (1999). Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 284, 147-151.
193. Wakasugi, K., Slike, B. M., Hood, J., Otani, A., Ewalt, K. L., Friedlander, M., et al. (2002). A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 99, 173-177.
194. Wantha, S., Alard, J. E., Megens, R. T., van der Does, A. M., Doring, Y., Drechsler, M., et al. (2013). Neutrophil-derived cathelicidin promotes adhesion of classical monocytes. Circ. Res. 112, 792-801.
195. Weber, C., Kraemer, S., Drechsler, M., Lue, H., Koenen, R. R., Kapurniotu, A., et al. (2008). Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc. Natl. Acad. Sci. U.S.A. 105, 16278-16283.
196. Weber, C., and Noels, H. (2011). Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 17, 1410-1422.
197. Weber, C., Schober, A., and Zernecke, A. (2004). Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler. Thromb. Vasc. Biol. 24, 1997-2008.
198. Wennogle, L. P., Conder, L., Winter, C., Braunwalder, A., Vlattas, S., Kramer, R., et al. (1994). Stabilization of C5a receptor - G-protein interactions through ligand binding. J. Cell. Biochem. 55, 380-388.
199. Wilson, S., Wilkinson, G., and Milligan, G. (2005). The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities. J. Biol. Chem. 280, 28663-28674.
200. Wu, B., Chien, E. Y., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., et al. (2010). Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071.
201. Wu, Y., Wang, S., Farooq, S. M., Castelvetere, M. P., Hou, Y., Gao, J. L., et al. (2012). A chemokine receptor CXCR2 macromolecular complex regulates neutrophil functions in inflammatory diseases. J. Biol. Chem. 287, 5744-5755.
202. Wymann, D., Bluggel, M., Kalbacher, H., Blesken, T., Akdis, C. A., Meyer, H. E., et al. (1999). Human B cells secrete migration inhibition factor (MIF) and present a naturally processed MIF peptide on HLA-DRB1*0405 by a FXXL motif. Immunology 96, 1-9.
203. Xie, L., Qiao, X., Wu, Y., and Tang, J. (2011). Beta-arrestin1 mediates the endocytosis and functions of macrophage migration inhibitory factor. PLoS ONE 6:e16428. doi:10.1371/journal.pone.0016428
204. Xu, Q., Leiva, M. C., Fischkoff, S. A., Handschumacher, R. E., and Lyttle, C. R. (1992). Leukocyte chemotactic activity of cyclophilin. J. Biol. Chem. 267, 11968-11971.
205. Yang, D., Biragyn, A., Hoover, D. M., Lubkowski, J., and Oppenheim, J. J. (2004). Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu. Rev. Immunol. 22, 181-215.
206. Yang, D., Chen, Q., Yang, H., Tracey, K. J., Bustin, M., and Oppenheim, J. J. (2007). High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukoc. Biol. 81, 59-66.
207. Yang, D., Chertov, O., Bykovskaia, S. N., Chen, Q., Buffo, M. J., Shogan, J., et al. (1999). Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286, 525-528.
208. Yang, D., Chertov, O., and Oppenheim, J. J. (2001). Participation of mammalian defensins and cathelicidins in anti-microbial immunity: receptors and activities of human defensins and cathelicidin (LL-37). J. Leukoc. Biol. 69, 691-697.
209. Yang, X. L., Skene, R. J., McRee, D. E., and Schimmel, P. (2002). Crystal structure of a human aminoacyl-tRNA synthetase cytokine. Proc. Natl. Acad. Sci. U.S.A. 99, 15369-15374.
210. Yende, S., Angus, D. C., Kong, L., Kellum, J. A., Weissfeld, L., Ferrell, R., et al. (2009). The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. FASEB J. 23, 2403-2411.
211. Yurchenko, V., Zybarth, G., O'Connor, M., Dai, W. W., Franchin, G., Hao, T., et al. (2002). Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J. Biol. Chem. 277, 22959-22965.
212. Zabel, B. A., Wang, Y., Lewen, S., Berahovich, R. D., Penfold, M. E., Zhang, P., et al. (2009). Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J. Immunol. 183, 3204-3211.
213. Zernecke, A., Bernhagen, J., and Weber, C. (2008). Macrophage migration inhibitory factor in cardiovascular disease. Circulation 117, 1594-1602.
214. Zhang, B., Shen, M., Xu, M., Liu, L. L., Luo, Y., Xu, D. Q., et al. (2012). Role of macrophage migration inhibitory factor in the proliferation of smooth muscle cell in pulmonary hypertension. Mediators Inflamm. 2012, 840737.
215. Zhang, Y., and Wang, H. (2012). Integrin signalling and function in immune cells. Immunology 135, 268-275.
216. Zou, Y. R., Kottmann, A. H., Kuroda, M., Taniuchi, I., and Littman, D. R. (1998). Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393, 595-599.